{"filing":{"accession_number":"0001104659-26-073429","cik":"0001850119","ticker":"IPSC","company_name":"Century Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tm2617728d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926073429/tm2617728d1_8k.htm"},"events":[{"id":10758,"run_id":9439,"accession_number":"0001104659-26-073429","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Century Therapeutics held its 2026 Annual Meeting of Stockholders on June 11, 2026, at which shareholders voted on and approved four proposals: election of Class II directors (Alessandro Riva and Han Lee), ratification of Ernst \u0026 Young LLP as independent auditor, approval of an amendment to the Certificate of Incorporation to increase authorized common shares from 300 million to 450 million, and approval of a potential meeting adjournment.","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":7152,"accession_number":"0001104659-26-073429","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes an amendment to the Certificate of Incorporation to increase authorized shares of common stock, approved by stockholders at the 2026 Annual Meeting and filed with Delaware on June 11, 2026. While this is a structural corporate action that could signal capital-raising intent or dilution risk, it is a routine administrative amendment to the charter rather than a specific material event type (not a dilutive issuance itself, not M\u0026A, not an executive change). The materiality lies in the potential for future dilution, making it material to investors, but the taxonomy lacks a dedicated category for charter amendments increasing authorized shares.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:03.691184+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7153,"accession_number":"0001104659-26-073429","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from Century Therapeutics' Annual Meeting held June 11, 2026. The filing reports final vote tallies for four proposals: election of Class II directors (Alessandro Riva and Han Lee), ratification of Ernst \u0026 Young LLP as independent auditor, approval of a certificate amendment to increase authorized common shares from 300M to 450M, and approval of a potential meeting adjournment. All proposals passed. The disclosure is material as it confirms shareholder approval of significant corporate actions including director elections and authorized share increases.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:03.691184+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7152,"accession_number":"0001104659-26-073429","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes an amendment to the Certificate of Incorporation to increase authorized shares of common stock, approved by stockholders at the 2026 Annual Meeting and filed with Delaware on June 11, 2026. While this is a structural corporate action that could signal capital-raising intent or dilution risk, it is a routine administrative amendment to the charter rather than a specific material event type (not a dilutive issuance itself, not M\u0026A, not an executive change). The materiality lies in the potential for future dilution, making it material to investors, but the taxonomy lacks a dedicated category for charter amendments increasing authorized shares.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:03.691184+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-06-12"},{"id":7153,"accession_number":"0001104659-26-073429","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from Century Therapeutics' Annual Meeting held June 11, 2026. The filing reports final vote tallies for four proposals: election of Class II directors (Alessandro Riva and Han Lee), ratification of Ernst \u0026 Young LLP as independent auditor, approval of a certificate amendment to increase authorized common shares from 300M to 450M, and approval of a potential meeting adjournment. All proposals passed. The disclosure is material as it confirms shareholder approval of significant corporate actions including director elections and authorized share increases.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:16:03.691184+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-06-12"}]}